Imatinib Mesylate Inhibits Bleomycin-Induced Pulmonary Fibrosis in Mice: the Mechanism

LI Li,LI Yan-qin
DOI: https://doi.org/10.3724/sp.j.1008.2009.00645
2009-01-01
Abstract:Objective:To observe the effect of imatinib mesylate on pulmonary fibrosis(PF)induced by bleomycin in mice and to explore the related mechanism.Methods:Totally 120 C57BL/6 mice were evenly randomized into control group,model group,dexamethasone group and imatinib group.The pulmonary fibrosis model was established using a single intratracheal infusion of bleomycin;the corresponding drugs were given to mice in each group.Ten mice was sacrificed in each group on day 7,14,and 21 after operation,respectively.The expression of matrix metalloproteinase 1(MMP-1),tissue inhibitor of metalloproteinase 1(TIMP-1),and transforming growth factor β1(TGF-β1)in the lung tissues was semi-quantitatively analyzed by immunohistochemistry method.Results:Immunohistochemistry results showed that the expression of TIMP-1,MMP-1,and TGF-β1 in lung tissues of the dexamethasone group and imatinib group was significantly lower than that in the model group(P0.01).There was a positive correlation between TGF-β1 and TIMP-1 expression(r=0.243,P=0.004).A negative correlation was found between MMP-1 and TIMP-1 in all the other 3 groups other than in the normal control group(r=-0.291,P0.000 1).Conclusion:Imatinib may downregulate TGF-β1 expression,inhibit TIMP-1 expression,and upregulate MMP-1 expression,maintaining the balance of TIMP-1/MMP-1,subsequently inhibit the development of pulmonary fibrosis,showing a similar effect of dexamethasone.
What problem does this paper attempt to address?